1 study of tamoxifen and raloxifene star larry wickerham, md nsabp star project officer
TRANSCRIPT
2
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
# EventsPlacebo 93Tamoxifen 60
50
40
30
20
10
0
# EventsPlacebo 250Tamoxifen 145
50
40
30
20
10
0
Cu
mu
lati
ve R
ate/
1000
Invasive Breast Cancer
NoninvasiveBreast Cancer
Time to Breast Cancer (Years)
P < 0.0001
P= 0.008
NSABP P1 Study
3
STRATIFICATION• Age• Gail Model Risk• Race• History of LCIS• Hysterectomy
Tamoxifen20 mg/dayx 5 years
Study DesignSTAR
Raloxifene60 mg/dayx 5 years
Risk-Eligible Postmenopausal Women
4
Inclusion and Exclusion CriteriaSTAR
Inclusion
– At least 35 years of age
– Postmenopausal
– Risk eligible
Lobular carcinoma in situ or
5-year Gail risk of breast cancer >1.66%
Exclusion
History of:
– Invasive breast cancer
– Ductal carcinoma in situ
– DVT, PE
– CVA, TIA
– Uncontrolled diabetes, hypertension or atrial fibrillation
5
Primary AimsSTAR
• The primary aim of the study was to determine which of the following three statements is true:
– Compared to tamoxifen, raloxifene significantly reduces the incidence rate of IBC
– Compared to raloxifene, tamoxifen significantly reduces the incidence rate of IBC
– The statistical superiority of one of the treatments cannot be demonstrated and the choice of therapy should be based on benefit/risk considerations
6
Primary ObjectiveSTAR
Evaluate the effect of raloxifene versus tamoxifen in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk.
7
Secondary Objectives STAR
•Non-invasive breast cancer
•Endometrial cancer
•Ischemic heart disease
•Fractures of the hip, spine or wrist
•Toxicity and side effects
8
Screening, Accrual and Follow-upSTAR
Screened 184,460
Eligible 96,368
Randomized 19,747
Woman-years of follow-up 79,173
Average follow-up (years) 4.06
9
Baseline CharacteristicsSTAR
Age (mean) 58.5
Caucasian 93%
Hysterectomy 51%
First degree relative(s)with breast cancer 71%
History of
Lobular carcinoma in situ 9%
Atypical hyperplasia 23%
5-year predicted Gail risk ofinvasive breast cancer (mean) 4.03%
10
Effects on Invasive Breast Cancer STAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve in
cid
ence
per
100
0 w
om
en
0
5
10
15
20
25
30Tamoxifen (n=168)Raloxifene (n=173)
RR (95% CI) = 1.02 (0.82, 1.27)
11
Invasive Breast Cancer STAR
0
2
4
6
8
10
12
Gail Model Expectedif Untreated
Tamoxifen Raloxifene
Inci
denc
e pe
r 10
00 w
oman
-yrs
168 173
325
12
Invasive Breast Cancer by 5-year Predicted RiskSTAR
0
2
4
6
8
10
12
≤3% 3.01 - 5% ≥5.01%
Predicted 5-year Risk
Inci
denc
e pe
r 10
00 w
oman
-yrs
Tamoxifen
Raloxifene
33
63
72
4449
80
13
Invasive Breast Cancer Tumor CharacteristicsSTAR
Tamoxifenn=168
Raloxifenen=173
Estrogen Receptor Status
+ 72% 69%
- 28% 31%
Tumor Size
<1 29% 39%
1.1-3 61% 54%
>3.1 10% 8%
Nodal Status
- 74% 80%
+ 26% 20%
14
0
3
6
9
12
Inci
den
ce p
er 1
000
wo
man
-yrs Tamoxifen
Raloxifene
LCISN=1783
Atypical Hyperplasia N=4429
34 35
4741
Invasive Breast Cancer in Women with aHistory of LCIS or Atypical Hyperplasia
STAR
15
Non-Invasive Breast Cancer STAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve
in
cid
en
ce
pe
r 1
00
0 w
om
en
0
5
10
15
20
25
30
Tamoxifen (n=60)Raloxifene (n=83)
RR (95% CI) = 1.38 (0.98-1.95)
16
Non-Invasive Breast CancerSTAR
Tamoxifen(n)
Raloxifene(n)
RR (95%CI)
DCIS 32 47 1.46 (0.91-2.37)
LCIS 23 29 1.26 (0.70-2.27)
Mixed 5 7 1.39 (0.38-5.57)
17
Uterine Cancer STAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve in
cid
ence
per
100
0 w
om
en
0
5
10
15
20
25
30Tamoxifen (n=37)Raloxifene (n=23)
RR (95% CI) = 0.61 (0.34, 1.05)
18
Tamoxifen(n)
Raloxifene(n)
RR (95% CI)
Hysterectomyduring study
246 92 0.37 (0.28, 0.47)
Hyperplasia 100 17 0.17 (0.09, 0.28)
with atypia 15 2 0.13 (0.01, 0.56)
w/o atypia 85 15 0.17 (0.09, 0.30)
Uterine Hyperplasia and HysterectomySTAR
19
Ischemic Heart Disease STAR
Tamoxifen(n)
Raloxifene(n)
RR (95% CI)
Myocardial infarction
53 39 0.73 (0.47-1.13)
Severe angina 55 71 1.28 (0.89-1.86)
Acute ischemic syndrome
17 28 1.64 (0.87-3.19)
Total 125 138 1.10 (0.86-1.41)
20
Osteoporotic Fractures STAR
Tamoxifen(n)
Raloxifene(n)
RR (95% CI)
Hip 28 26 0.92 (0.52-1.63)
Spine 58 58 0.99 (0.68-1.46)
Wrist 27 27 0.99 (0.56-1.76)
Total* 111 108 0.97 (0.73-1.27)
*Columns not additive because one patient may have had fractures at multiple sites.
21
MortalitySTAR
Tamoxifen(n)
Raloxifene(n)
Cancer 52 52
Breast cancer 5 2
Circulatory/vascular 25 21
Other 32 31
Any cause 109 104RR (95% CI)
0.95 (0.72-1.25)
22
Venous Thromboembolic EventsSTAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve
in
cid
en
ce
pe
r 1
00
0 w
om
en
0
5
10
15
20
25
30Tamoxifen (n=150)Raloxifene (n=105)
RR (95% CI) = 0.69 (0.53, 0.90)
23
Cataracts and Cataract Surgery During Follow-upSTAR
0
2
4
6
8
10
12
14
Cataracts Cataract Surgery
Incid
en
ce p
er
1000 w
om
an
-yrs Tamoxifen
Raloxifene435
295
343
240
RR = 0.78(95% CI = 0.68–0.91)
RR = 0.81(95% CI = 0.68–0.96)